BLPH Bellerophon Therapeutics Inc.

0.65
+0.01  (+1%)
Previous Close 0.64
Open 0.67
Price To Book 10.85
Market Cap 44858304
Shares 68,906,765
Volume 163,543
Short Ratio
Av. Daily Volume 254,956

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b cohort 2 data and pivotal cohort 3 (Phase 3) initiation due 2H 2019.
INOpulse delivery device
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD)
Phase 3 trial stopped due to futility - August 7, 2018.
INOpulse delivery device
Pulmonary Arterial Hypertension (PAH)
Phase 2 trial complete. Evaluating next steps for program.
INOpulse delivery device
Pulmonary Hypertension associated with COPD (PH-COPD)
Phase 2 data due later in 2019.
INOpulse delivery device
Pulmonary hypertension associated with Sarcoidosis (PH-Sarcoidosis)

Latest News

  1. Bellerophon Announces Agreement with FDA on Regulatory Approval Pathway for INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
  2. Did Changing Sentiment Drive Bellerophon Therapeutics’s (NASDAQ:BLPH) Share Price Down A Painful 76%?
  3. Bellerophon Therapeutics: 4Q Earnings Snapshot
  4. Bellerophon Provides Business Update and Reports Fourth Quarter and Full-Year 2018 Financial Results
  5. Bellerophon to Present Clinical Data Supporting Actigraphy as a Clinically Meaningful Endpoint to Detect Improvements in Pulmonary Fibrosis Patients  
  6. Bellerophon Announces Closing of $7 Million Public Offering of Common Stock
  7. Bellerophon Announces Pricing of $7 Million Public Offering of Common Stock
  8. Bellerophon Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
  9. Bellerophon Announces Top-line Results from Cohort 1 of the INOpulse® Phase 2b Clinical Trial for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
  10. Analysis: Positioning to Benefit within KemPharm, Bellerophon Therapeutics, Exela Technologies, Intec Pharma, Cerecor, and Chiasma — Research Highlights Growth, Revenue, and Consolidated Results
  11. DBV Technologies Appoints Daniel Tassé as Chief Executive Officer
  12. Bellerophon Provides Business Update and Reports Third Quarter 2018 Financial Results
  13. 3 Biotech & Marijuana Stocks to Pay Attention to this Quarter
  14. Today’s Research Reports on Stocks to Watch:Tesla and Bellerophon Therapeutics
  15. The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict